UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 30, 2013
LeMaitre Vascular, Inc.
(Exact name of registrant as specified in its charter)
Commission File Number: 001-33092
| Delaware | 04-2825458 | |
| (State or other jurisdiction of | (IRS Employer | |
| incorporation) | Identification No.) |
63 Second Avenue
Burlington, MA 01803
(Address of principal executive offices, including zip code)
781-221-2266
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02. Results of Operations and Financial Condition
On July 30, 2013, LeMaitre Vascular, Inc. (the “Company”) issued a press release regarding its financial and operational results for the second quarter ended June 30, 2013. A copy of the press release is furnished as Exhibit 99.1 to this report.
The information in this report, including the Exhibit attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits
The following exhibit is furnished as part of this report, where indicated:
| (d) | Exhibits. |
| Exhibit |
Description | |
| 99.1 | Press release issued by LeMaitre Vascular, Inc. on July 30, 2013. | |
Signature(s)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| LeMaitre Vascular, Inc. | ||||||
| Date: July 30, 2013 | By: | Joseph P. Pellegrino, Jr. /s/ JOSEPH P. PELLEGRINO, JR. | ||||
| Joseph P. Pellegrino, Jr. Chief Financial Officer | ||||||
Exhibit Index
| Exhibit No. |
Description | |
| 99.1 | Press release issued by LeMaitre Vascular, Inc. on July 30, 2013. | |
Exhibit 99.1
For information contact:
J.J. Pellegrino
Chief Financial Officer
LeMaitre Vascular, Inc.
781-425-1691
jpellegrino@lemaitre.com
LeMaitre Q2 2013 Record Sales $16mm (+12% Organic), Op. Income $1.4mm
- Third Straight Double Digit Growth Quarter -
BURLINGTON, MA, July 30, 2013 — LeMaitre Vascular, Inc. (NASDAQ: LMAT), a provider of peripheral vascular devices and implants, today reported Q2 2013 financial results. The Company posted record sales of $16.0mm and operating income of $1.4mm. The Company also announced a $0.03 per share dividend and provided Q3 2013 and full-year 2013 guidance.
Q2 2013 reported sales grew 11% vs. Q2 2012. International sales increased 19%, while the Americas grew 7%. XenoSure posted record sales of $2.0mm in the quarter, a 56% year-over-year improvement. Organic growth was 12% in Q2 2013 and unit growth was 7%.
Gross margin in Q2 2013 was 70.4% vs. 73.4% in Q2 2012. The decrease was due to UnBalloon inventory write-offs, manufacturing inefficiencies, XenoSure transition costs, and mix shift towards faster-growing, lower-margin, XenoSure and international sales.
Q2 2013 operating income was $1.4mm, flat vs. Q2 2012. The 11% sales increase was offset by a lower gross margin and higher operating expenses. Q2 2013 net income increased to $0.9mm, or $0.06 per diluted share, up from $0.8mm, or $0.05 per diluted share in Q2 2012.
George W. LeMaitre, Chairman and CEO commented, “Q2 2013 was excellent. We posted our third straight double digit quarter. International sales were up 19% and our new Canadian subsidiary delivered 42% growth. In addition, in July we made a tuck-in acquisition which should boost our market share in shunts & catheters.”
Total operating expenses in Q2 2013 were $9.8mm, vs. $9.1mm in the year earlier quarter. This 8% increase was driven by higher administrative costs including expenses from the new Canadian subsidiary, higher selling costs and the Affordable Care Act tax. The Company ended Q2 2013 with 85 sales representatives, up from 83 in the prior year period.
Cash and marketable securities were $14.9mm at June 30, 2013, a $400,000 decrease in the quarter largely driven by two quarterly dividend payments totaling $0.9mm and XenoSure clean room construction of $0.7mm, offset by cash from operations.
Inventory Valuation Adjustment
The Company’s Q2 2013 financial results are preliminary, as management is currently evaluating historical inventory valuations related to misclassified manufacturing hours, which impact financial results for 2011, 2012 and the first six months of 2013, and whether prior period financial statements need to be revised. Based on the current status of its review, which is preliminary and subject to change, the attached Q2 2013 financial results reflect the correction of this error, which increased net income during Q2 2013 by approximately $0.3mm.
Any potential revisions to the 2011 and 2012 financial statements would increase reported net income in those periods by approximately $0.4mm and decrease Q2 2013 net income by $0.3mm. The Company expects that on a cumulative basis the sum of all potential period adjustments would be negligible to net income. Cash would remain unaffected by any adjustment. The Company is working to complete its evaluation. All figures presented in this section are still under review.
Quarterly Dividend
On July 24th 2013, the Company’s Board of Directors approved a quarterly cash dividend of $0.03 per share of common stock. The dividend will be paid on September 4, 2013 to shareholders of record on August 21, 2013. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to the determination of the Board of Directors.
Clinical Instruments
On July 5, 2013 LeMaitre Vascular acquired the assets of Clinical Instruments International, Inc. (“CII”), a manufacturer of carotid shunts and embolectomy catheters. CII, based in Southbridge, Massachusetts, posted sales of $635,000 in 2012. Total consideration for the acquisition is $1.1mm, of which $900,000 was paid at closing.
Business Outlook
The Company expects Q3 2013 sales of $15.2mm (+10% organic versus Q3 2012), and operating income of $1.1mm (7% operating margin). The Company increased its 2013 full-year sales guidance to $62.3mm (+10% organic vs. 2012), and maintained its full year operating income guidance to $5.0 mm (8% operating margin). The Company also increased its 2013 XenoSure sales guidance to $7.3mm.
All guidance excludes the effects of changes in foreign currency exchange rates as well as future acquisitions and divestitures.
Page 2
Conference Call Reminder
Management will conduct a conference call at 5:00 p.m. ET today to review the Company’s financial results and discuss its business outlook for the remainder of the year. The conference call will be broadcast live over the Internet. Individuals who are interested in listening to the webcast should log on to the Company’s website at www.lemaitre.com/investor. The conference call may also be accessed by dialing 800-638-4817 (+1 617-614-3943 for international callers), using pass-code 58261146. For individuals unable to join the live conference call, a replay will be available on the Company’s website.
A reconciliation of GAAP to non-GAAP (“organic”) results is included in the tables attached to this release.
About LeMaitre Vascular
LeMaitre Vascular is a provider of devices for the treatment of peripheral vascular disease, a condition that affects more than 20 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.
LeMaitre and the LeMaitre Vascular logo are registered trademarks of LeMaitre Vascular, Inc. This press release contains other trademarks and trade names of the Company.
For more information about the Company, please visit http://www.lemaitre.com.
Use of Non-GAAP Financial Measures
LeMaitre Vascular management believes that in order to better understand the Company’s short-term and long-term financial trends, investors may wish to consider certain non-GAAP financial measures as a supplement to financial performance measures prepared in accordance with GAAP. Non-GAAP financial measures are not based on a comprehensive set of accounting
Page 3
rules or principles and do not have standardized meanings. These non-GAAP measures result from facts and circumstances that may vary in frequency and/or impact on continuing operations. Non-GAAP measures should be considered in addition to, and not as a substitute for, financial performance measures in accordance with GAAP. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release.
In this press release, the Company has reported non-GAAP sales and growth percentages after adjusting for the impact of foreign currency exchange, business development transactions, and other events. The Company refers to this calculation of non-GAAP sales amounts and percentages as “organic.” The Company analyzes non-GAAP sales on a constant currency basis, net of acquisitions and other non-recurring events, to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions, product discontinuations, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency basis net of such transactions provides an additional and meaningful assessment of sales to management.
Forward-Looking Statements
The Company’s current financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company’s business that are not historical facts may be “forward-looking statements” that involve risks and uncertainties. Specifically, forward-looking statements in this release include, but are not limited to, statements about the Company’s expectations regarding Q2 2013 and 2013 sales and operating income levels. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected, including, but not limited to, the risk that prior period financial statements will need to be restated; the risk that assumptions about the market for the Company’s products and the productivity of the Company’s direct sales force and distributors may not be correct; risks related to the integration of acquisition targets; risks related to product demand and market acceptance of the Company’s products; the risk that the XenoSure product is not as accretive and does not achieve the gross margins currently anticipated by the Company; the risk that the Company experiences increased expense, production delays or quality difficulties in the transition of the XenoSure manufacturing operations; risks related to attracting, training and retaining sales representatives and other employees in new markets such as Switzerland and Canada; the risk that the Company is not successful in transitioning to a direct-selling model in new territories; adverse conditions in the general domestic and global economic markets and other risks and uncertainties included under the heading “Risk Factors” in our most recent Annual Report on Form 10-K, as updated by our subsequent filings with the SEC, all of which are available on the Company’s investor relations website at http://www.lemaitre.com and on the SEC’s website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
Page 4
Financial Statements
LEMAITRE VASCULAR, INC (NASDAQ: LMAT)
CONDENSED CONSOLIDATED BALANCE SHEETS
(amounts in thousands)
| June 30, 2013 | December 31, 2012 | |||||||
| (unaudited) | ||||||||
| Assets |
||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 14,910 | $ | 16,448 | ||||
| Accounts receivable, net |
9,714 | 9,048 | ||||||
| Inventories |
11,654 | 10,859 | ||||||
| Other current assets |
2,557 | 2,776 | ||||||
|
|
|
|
|
|||||
| Total current assets |
38,835 | 39,131 | ||||||
| Property and equipment, net |
5,836 | 4,544 | ||||||
| Goodwill |
13,749 | 13,749 | ||||||
| Other intangibles, net |
4,840 | 5,191 | ||||||
| Deferred tax assets |
259 | 273 | ||||||
| Other assets |
156 | 172 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 63,675 | $ | 63,060 | ||||
|
|
|
|
|
|||||
| Liabilities and stockholders’ equity |
||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | 1,011 | $ | 1,060 | ||||
| Accrued expenses |
5,937 | 6,777 | ||||||
| Acquisition-related obligations |
508 | 557 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
7,456 | 8,394 | ||||||
| Deferred tax liabilities |
1,673 | 1,673 | ||||||
| Other long-term liabilities |
415 | 105 | ||||||
|
|
|
|
|
|||||
| Total liabilities |
9,544 | 10,172 | ||||||
| Stockholders’ equity |
||||||||
| Common stock |
166 | 165 | ||||||
| Additional paid-in capital |
64,524 | 64,694 | ||||||
| Accumulated deficit |
(2,134 | ) | (3,869 | ) | ||||
| Accumulated other comprehensive loss |
(653 | ) | (433 | ) | ||||
| Less: treasury stock |
(7,772 | ) | (7,669 | ) | ||||
|
|
|
|
|
|||||
| Total stockholders’ equity |
54,131 | 52,888 | ||||||
|
|
|
|
|
|||||
| Total liabilities and stockholders’ equity |
$ | 63,675 | $ | 63,060 | ||||
|
|
|
|
|
|||||
Page 5
LEMAITRE VASCULAR, INC (NASDAQ: LMAT)
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(amounts in thousands, except per share amounts)
(unaudited)
| For the three months ended | For the six months ended | |||||||||||||||
| June 30, 2013 | June 30, 2012 | June 30, 2013 | June 30, 2012 | |||||||||||||
| Net sales |
$ | 15,951 | $ | 14,361 | $ | 31,333 | $ | 28,289 | ||||||||
| Cost of sales |
4,714 | 3,816 | 8,890 | 7,874 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Gross profit |
11,237 | 10,545 | 22,443 | 20,415 | ||||||||||||
| Operating expenses: |
||||||||||||||||
| Sales and marketing |
5,305 | 5,186 | 11,073 | 10,399 | ||||||||||||
| General and administrative |
3,067 | 2,717 | 5,949 | 5,385 | ||||||||||||
| Research and development |
1,268 | 1,135 | 2,541 | 2,270 | ||||||||||||
| Loss on divestitures |
— | 52 | — | 52 | ||||||||||||
| Medical device excise tax |
150 | — | 310 | — | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
9,790 | 9,090 | 19,873 | 18,106 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Income from operations |
1,447 | 1,455 | 2,570 | 2,309 | ||||||||||||
| Other income (loss): |
||||||||||||||||
| Interest income (expense), net |
(6 | ) | 14 | (9 | ) | 21 | ||||||||||
| Other income (loss), net |
(66 | ) | (49 | ) | (116 | ) | (247 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total other loss, net |
(72 | ) | (35 | ) | (125 | ) | (226 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Income before income taxes |
1,375 | 1,420 | 2,445 | 2,083 | ||||||||||||
| Provision for income taxes |
486 | 596 | 710 | 873 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net income |
$ | 889 | $ | 824 | $ | 1,735 | $ | 1,210 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Earnings per share of common stock: |
||||||||||||||||
| Basic |
$ | 0.06 | $ | 0.05 | $ | 0.11 | $ | 0.08 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Diluted |
$ | 0.06 | $ | 0.05 | $ | 0.11 | $ | 0.08 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Weighted-average shares outstanding: |
||||||||||||||||
| Basic |
15,250 | 15,201 | 15,234 | 15,248 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Diluted |
15,701 | 15,636 | 15,676 | 15,681 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Cash dividends declared per common share |
$ | 0.030 | $ | 0.025 | $ | 0.060 | $ | 0.050 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
Page 6
LEMAITRE VASCULAR, INC (NASDAQ: LMAT)
SELECTED NET SALES INFORMATION
(amounts in thousands)
(unaudited)
| For the three months ended | For the six months ended | |||||||||||||||||||||||||||||||
| June 30, 2013 | June 30, 2012 | June 30, 2013 | June 30, 2012 | |||||||||||||||||||||||||||||
| $ | % | $ | % | $ | % | $ | % | |||||||||||||||||||||||||
| Net Sales by Geography |
||||||||||||||||||||||||||||||||
| Americas |
$ | 10,363 | 65 | % | $ | 9,676 | 67 | % | $ | 20,611 | 66 | % | $ | 19,150 | 68 | % | ||||||||||||||||
| International |
5,588 | 35 | % | 4,685 | 33 | % | 10,722 | 34 | % | 9,139 | 32 | % | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Total Net Sales |
$ | 15,951 | 100 | % | $ | 14,361 | 100 | % | $ | 31,333 | 100 | % | $ | 28,289 | 100 | % | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
LEMAITRE VASCULAR, INC (NASDAQ: LMAT)
NON-GAAP FINANCIAL MEASURES
(amounts in thousands)
(unaudited)
| Reconciliation between GAAP and Non-GAAP sales growth: |
||||||||||||
| For the three months ending June 30, 2013 |
||||||||||||
| Net sales as reported |
$ | 15,951 | ||||||||||
| Impact of currency exchange rate fluctuations |
70 | |||||||||||
|
|
|
|||||||||||
| Adjusted net sales |
$ | 16,021 | ||||||||||
| For the three months ending June 30, 2012 |
||||||||||||
| Net sales as reported |
$ | 14,361 | ||||||||||
|
|
|
|||||||||||
| Adjusted net sales increase for the three months ending June 30, 2013 |
$ | 1,660 | 12 | % | ||||||||
|
|
|
|
|
|||||||||
| Reconciliation between GAAP and Non-GAAP sales growth for Quarterly Guidance: |
||||||||||||
| For the three months ending September 30, 2013 |
||||||||||||
| Net sales per guidance |
$ | 15,200 | ||||||||||
| Net impact of acquisitions and distributed sales excluding currency |
$ | (75 | ) | |||||||||
| Impact of currency exchange rate fluctuations |
(100 | ) | ||||||||||
|
|
|
|||||||||||
| Adjusted net sales |
$ | 15,025 | ||||||||||
| For the three months ending September 30, 2012 |
||||||||||||
| Net sales as reported |
$ | 13,645 | ||||||||||
|
|
|
|||||||||||
| Adjusted net sales increase for the three months ending September 30, 2013 |
$ | 1,380 | 10 | % | ||||||||
|
|
|
|
|
|||||||||
| Reconciliation between GAAP and Non-GAAP sales growth for Annual Guidance: |
||||||||||||
| For the year ending December 31, 2013 |
||||||||||||
| Net sales per guidance |
$ | 62,300 | ||||||||||
| Net impact of acquisitions and distributed sales excluding currency |
$ | (200 | ) | |||||||||
| Impact of currency exchange rate fluctuations |
57 | |||||||||||
|
|
|
|||||||||||
| Adjusted net sales |
$ | 62,157 | ||||||||||
| For the year ending December 31, 2012 |
||||||||||||
| Net sales as reported |
$ | 56,735 | ||||||||||
|
|
|
|||||||||||
| Adjusted net sales increase for the year ending December 31, 2013 |
$ | 5,422 | 10 | % | ||||||||
|
|
|
|
|
|||||||||
Page 7